NCT05519059View on ClinicalTrials.gov

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

September 29, 2022

Study Completion Date

May 30, 2023

Conditions
Advanced or Metastatic Breast Cancer
Interventions
DRUG

Pelareorep

Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle

Trial Locations (1)

130012

Bethune First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Adlai Nortye Biopharma Co., Ltd.

INDUSTRY

NCT05519059 - Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter